AbbVie Inc., North Chicago, IL, USA.
Abbott Laboratories, EDP Global Pharmacovigilance, Hannover, Germany.
J Parkinsons Dis. 2018;8(1):141-144. doi: 10.3233/JPD-161057.
The independent contribution of levodopa exposure and Parkinson's disease (PD) to the risk of polyneuropathy is not established.
This study investigated whether patients with newly diagnosed PD without previous exposure to antiparkinsonian drugs have higher prevalence of polyneuropathy than the general population.
Using the UK General Practice Research Database, presence of polyneuropathy in the previous 3 years was assessed.
Of 5089 PD patients and 19,897 controls, polyneuropathy was confirmed in 15 PD patients (0.29% ) and 24 controls (0.12% ). Polyneuropathy prevalence was 2.4-fold higher in PD patients than controls.
In this observational study, PD patients had a higher prevalence of preexisting polyneuropathy that cannot be explained by adverse effects of antiparkinsonian drugs.
左旋多巴暴露和帕金森病（PD）对周围神经病风险的独立贡献尚不清楚。
本研究旨在调查新诊断为 PD 且无既往抗帕金森病药物暴露的患者是否比一般人群有更高的周围神经病患病率。
利用英国全科医生研究数据库，评估过去 3 年内是否存在周围神经病。
在 5089 例 PD 患者和 19897 例对照者中，15 例 PD 患者（0.29%）和 24 例对照者（0.12%）确诊为周围神经病。PD 患者的周围神经病患病率是对照组的 2.4 倍。
在这项观察性研究中，PD 患者存在更高的预先存在的周围神经病患病率，这不能用抗帕金森病药物的不良反应来解释。
